Clarivate (CLVT) Stock Slumps As Impairment Loss Clouds AI Progress

Clarivate stock closed at US$2.01, down 6.5% on the day, even as the earnings print put a very different spotlight on the business. The headline was not the top line. It was a heavy net loss of US$268.6m in the quarter, driven by a non cash impairment tied to the planned Life Sciences and Health sale.

Short term traders focused on the red ink. Longer term investors are likely to focus on the adjusted engine behind it, with adjusted EBITDA margin around the low 40s and recurring revenue and artificial intelligence product rollout taking center stage later in this earnings story.

Love Clarivate's high adjusted EBITDA margin and recurring revenue profile but concerned about the heavy quarterly net loss tied to impairments? Take a look at our screener of list of solid balance sheet and fundamentals stocks (46 results) to compare Clarivate against companies where profitability and balance sheet strength line up more cleanly.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$587.3 million vs. US$621.4 million (decline of 5.5%)
• Net Loss, Q2 2026 vs. Q2 2025: US$268.6 million loss vs. US$72.0 million loss (loss widened by 273.1%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.42 loss per share vs. US$0.11 loss per share (loss per share worsened by 297.6%)
• Adjusted EBITDA Margin, Q2 2026: Low 40s percent range, with management pointing to around 42% to 43% as the reference level for the quarter

Prefer clean charts instead of another wall of earnings tables and impairment footnotes? See Clarivate's full financial picture, with an at-a-glance view of its valuation setup, in our company report for Clarivate.

Clarivate bull case hinges on recurring and AI proof points

Bulls argue Clarivate is turning into a higher quality, AI led, subscription heavy cash generator. The quarter offers some support, but also shows how early this shift still is. Adjusted EBITDA margin in the low 40s and free cash flow of US$44m on US$587.3m of revenue fit the story of a more efficient, subscription focused model. Organic annual contract value growth of 1.5%, with A&G and Life Sciences & Health at about 2%, shows recurring revenue inching forward rather than breaking out. New AI products like Web of Science Research Intelligence with 77 paying customers and IPOne, plus wins such as national library deals and USPTO AI image search, give evidence that Clarivate’s data and AI can win real contracts. Guidance for roughly US$1b adjusted EBITDA and recurring organic growth near 1.5% suggests operational progress but not yet a clear growth inflection.

Clarivate bear case focuses on revenue drag and leverage risk

Bears worry that shrinking transactional revenue, portfolio pruning and leverage will keep Clarivate stuck with weak growth and heavy risk. The 5.5% revenue decline to US$587.3m and widening quarterly net loss to US$268.6m, even if impairment driven, give that concern some fuel. Headline revenue is under pressure as disposals and lower transactional activity bite, and management now expects full year revenue slightly below the midpoint near US$2.35b. Organic ACV at 1.5% and flat recurring IP revenue show that subscription growth is not yet strong enough to fully offset those drags. At the same time, debt reduction of about US$218m year to date, US$75m of 2028 bonds repurchased, and a planned US$600m LS&H sale aimed at cutting leverage all work directly against the balance sheet risk that bears highlight.

Compare Clarivate’s high margin, recurring revenue story with the sharp earnings loss and the recent 6.5% share price drop, then consider whether the analyst community views this reset as an opportunity or a warning sign. See the consensus price target analysis for Clarivate to check how Wall Street targets line up with the latest earnings mix.

Stay Ahead With Simply Wall St

If Clarivate's mix of high adjusted EBITDA margin, recurring revenue and a sharp quarterly net loss has your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the story develops. After you decide to take a position, use the Portfolio Command Center to keep your holdings organised and receive focused, critical updates without the noise. For a broader view on Clarivate and similar stocks, tap into the Community to see how other investors are thinking through the same trade offs. By identifying potential catalysts and risks early, you may be able to act before the rest of the market responds.

Seeking Alternatives Beyond Clarivate?

Fresh stock ideas can move from quiet accumulation to breakout momentum fast. Use curated screeners to spot companies still under the radar for now, then act now.

• Pinpoint resilient compounders before sentiment turns by scanning hand picked 89 resilient stocks with low risk scores that aim to hold up when volatility picks up and confidence fades.
• Chase real earnings power instead of hype by reviewing curated 65 profitable AI stocks that aren't just burning cash where cash generation and AI exposure move together, not in opposite directions.
• Target potential income workhorses while yields still look appealing by checking pre filtered 8 dividend fortresses that focus on consistency, coverage and balance sheet support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com